FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions

Blood

Volumn 112, Issue 13, 2008, Pages 4953-4960

  Ahmadzadeh, Mojgan ^a   Felipe Silva, Aloisio ^a   Heemskerk, Bianca ^a   Powell Jr , Daniel J ^a   Wunderlich, John R ^a   Merino, Maria J ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; TRANSCRIPTION FACTOR FOXP3; CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; CELL SUSPENSION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIGESTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; MELANOMA; MICROENVIRONMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; BIOSYNTHESIS; CHEMISTRY; IMMUNOLOGY; LYMPHOCYTE COUNT; METASTASIS; MULTIPLE MYELOMA; PATHOLOGY;

CYTOKINES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LYMPHOCYTE COUNT; MULTIPLE MYELOMA; NEOPLASM METASTASIS; T-LYMPHOCYTES, REGULATORY;

EID: 58149399352     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-06-163048     Document Type: Article

References (45)

1. Baecher-Allan C, Viglietta V, Hafler DA. Human CD4+CD25+ regulatory Tcells. Semin Immunol. 2004;16:89-98.
2. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531-562.
3. Hori S, NomuraT, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057-1061.
4. Fontenot JD, RudenskyAY. Awell adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol. 2005;6:331-337.
5. Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol. 2006;24:209-226.
6. Khattri R, CoxT, Yasayko SA, Ramsdell F An essential role for Scurfin in CD4 + CD25+ T regulatory cells. Nat Immunol. 2003;4:337-342.
7. Wildin RS, Ramsdell F, Peake J, et al. X-linked neonatal diabetes mellitus, enteropathy and en-docrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 2001;27:18-20.
8. Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8 + CD25+ Tregs. J Clin Invest. 2005;115:2904-2913.
9. Gavin MA, Torgerson TR, Houston E, et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA. 2006;103:6659-6664.
10. Ahmadzadeh M, Antony PA, Rosenberg SA. IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8T cells. J Immunother. 2007;30:294-302.
11. Walker MR, Carson BD, Nepom GT, Ziegler SF Buckner JH. De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4 + CD25-cells. Proc Natl Acad Sci USA. 2005;102:4103-4108.
12. Antony PA, Paulos CM, Ahmadzadeh M, etal. Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J Immunol. 2006;176: 5255-5266.
13. Antony PA, Piccirillo CA, Akpinarli A, et al. CD8 + Tcell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005;174:2591-2601.
14. Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4 + CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating Tcells. J Immunol. 2004;173:1444-1453.
15. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory Tcells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756-2761.
16. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-949.
17. Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002;168:4272-4276.
18. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003;26:332-342.
19. Powell DJ, Jr., Felipe-Silva A, Merino MJ, et al. Administration of a CD25-directed immuno-toxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol. 2007;179: 4919-4928.
20. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM. Cutting edge: IL-2 is critically required for the in vitro activation of CD4 + CD25 + Tcell suppressor function. J Immunol. 2004;172: 6519-6523.
21. Fontenot JD, Rasmussen JP, Gavin MA, RudenskyAY. Afunction for interleukin 2 in Foxp3-expressing regulatory Tcells. Nat Immunol. 2005;6:1142-1151.
22. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
23. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol. 2001;167:1245-1253.
24. Ruprecht CR, Gattorno M, Ferlito F, et al. Coexpression of CD25 and CD27 identifies FoxP3 + regulatory Tcells in inflamed synovia. J Exp Med. 2005;201:1793-1803.
25. Rosenberg SA, Sportes C, Ahmadzadeh M, et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother. 2006;29:313-319.
26. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203:1701-1711.
27. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5:263-274.
28. Miller AM, Lundberg K, Ozenci V, et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 2006;177:7398-7405.
29. Vence L, PaluckaAK, Fay JW, et al. Circulating tumor antigen-specific regulatory Tcells in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2007;104:20884-20889.
30. Wang HY, Lee DA, Peng G, et al. Tumor-specific human CD4+ regulatory Tcells and their ligands: implications for immunotherapy. Immunity. 2004;20:107-118.
31. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatoryTcell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U SA. 2005;102:18538-18543.
32. Rezvani K, Mielke S, Ahmadzadeh M, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT Blood. 2006;108:1291-1297.
33. Zhang H, Chua KS, Guimond M, et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4 + CD25+ regulatory Tcells. Nat Med. 2005;11:1238-1243.
34. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory Tcells in cancer patients. Blood. 2006;107: 2409-2414.
35. Valzasina B, Piconese S, Guiducci C, Colombo MP. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res. 2006;66:4488-4495.
36. Zhou G, Levitsky HI. Natural regulatory Tcells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol. 2007;178:2155-2162.
37. Van Belle P, Rodeck U, Nuamah I, Halpern AC, Elder DE. Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol. 1996;148:1887-1894.
38. Yamagiwa S, Gray JD, Hashimoto S, Horwitz DA. A role for TGF-betain the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J Immunol. 2001;166: 7282-7289.
39. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4 + CD25- naive T cells to CD4+CD25+ regulatory Tcells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198:1875-1886.
40. Yamazaki S, Bonito AJ, Spisek R, Dhodapkar M, Inaba K, Steinman RM. Dendritic cells are specialized accessory cells along with TGF- for the differentiation of Foxp3+ CD4+ regulatory T cells from peripheral Foxp3 precursors. Blood. 2007;110:4293-4302.
41. Zheng SG, Wang JH, Koss MN, Quismorio F Jr, Gray JD, Horwitz DA. CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-beta suppress a stimulatory graft-versus-host disease with a lupus-like syndrome. J Immunol. 2004;172:1531-1539.
42. Powell DJ, Jr., de Vries CR, Allen T, Ahmadzadeh M, Rosenberg SA. Inability to mediate prolonged reduction of regulatory T cells after transfer of autologous CD25-depleted PBMC and interleu-kin-2 after lymphodepleting chemotherapy. J Im-munother. 2007;30:438-447.
43. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother. 2005;28:582-592.
44. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005;115:3623-3633.
45. Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med. 2008;205:825-839.